- Home
- COYA vs HURA Comparison
COYA vs HURA Comparison
Compare COYA & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COYA
- HURA
- Stock Information
- Founded
- COYA 2020
- HURA 2009
- Country
- COYA United States
- HURA United States
- Employees
- COYA N/A
- HURA N/A
- Industry
- COYA Biotechnology: Pharmaceutical Preparations
- HURA
- Sector
- COYA Health Care
- HURA
- Exchange
- COYA Nasdaq
- HURA Nasdaq
- Market Cap
- COYA 99.8M
- HURA 103.3M
- IPO Year
- COYA 2022
- HURA N/A
- Fundamental
- Price
- COYA $6.67
- HURA $2.85
- Analyst Decision
- COYA Strong Buy
- HURA Strong Buy
- Analyst Count
- COYA 4
- HURA 2
- Target Price
- COYA $16.50
- HURA $11.50
- AVG Volume (30 Days)
- COYA 88.2K
- HURA 427.2K
- Earning Date
- COYA 08-11-2025
- HURA 08-15-2025
- Dividend Yield
- COYA N/A
- HURA N/A
- EPS Growth
- COYA N/A
- HURA N/A
- EPS
- COYA N/A
- HURA N/A
- Revenue
- COYA $3,685,107.00
- HURA N/A
- Revenue This Year
- COYA $21.49
- HURA N/A
- Revenue Next Year
- COYA N/A
- HURA $69.15
- P/E Ratio
- COYA N/A
- HURA N/A
- Revenue Growth
- COYA N/A
- HURA N/A
- 52 Week Low
- COYA $4.65
- HURA $1.80
- 52 Week High
- COYA $10.24
- HURA $9.01
- Technical
- Relative Strength Index (RSI)
- COYA 65.20
- HURA N/A
- Support Level
- COYA $5.66
- HURA N/A
- Resistance Level
- COYA $6.07
- HURA N/A
- Average True Range (ATR)
- COYA 0.32
- HURA 0.00
- MACD
- COYA 0.06
- HURA 0.00
- Stochastic Oscillator
- COYA 88.60
- HURA 0.00
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.